{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:02:06Z","timestamp":1791464526035,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.chest.2026.03.040","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:50:48Z","timestamp":1776783048000},"page":"1114-1125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Antifibrotic Adherence and Dosing on Risk of Mortality and Hospitalization in Idiopathic Pulmonary Fibrosis"],"prefix":"10.1016","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4025-6401","authenticated-orcid":false,"given":"Huiping","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta S.","family":"Chhabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"DeDent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siu L.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-1311","authenticated-orcid":false,"given":"Ryan D.","family":"Boente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.chest.2026.03.040_bib1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"10.1016\/j.chest.2026.03.040_bib2","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","article-title":"Nerandomilast in patients with idiopathic pulmonary fibrosis","volume":"392","author":"Richeldi","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.chest.2026.03.040_bib3","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.chest.2026.03.040_bib4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2026.03.040_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01299-2023","article-title":"Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis","volume":"62","author":"Dempsey","year":"2023","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.chest.2026.03.040_bib6","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1513\/AnnalsATS.202312-1054OC","article-title":"Effect of antifibrotic use on mortality in patients with idiopathic pulmonary fibrosis","volume":"21","author":"Xu","year":"2024","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"10.1016\/j.chest.2026.03.040_bib7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1513\/AnnalsATS.202007-901OC","article-title":"Adoption of the antifibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis","volume":"18","author":"Dempsey","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.chest.2026.03.040_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12890-023-02565-7","article-title":"Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment","volume":"23","author":"Herberts","year":"2023","journal-title":"BMC Pulm Med"},{"issue":"145","key":"10.1016\/j.chest.2026.03.040_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0053-2017","article-title":"When to start and when to stop antifibrotic therapies","volume":"26","author":"Torrisi","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.chest.2026.03.040_bib10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12890-020-01224-5","article-title":"Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study","volume":"20","author":"Corral","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.chest.2026.03.040_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107015","article-title":"Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis","volume":"204","author":"Porse","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2026.03.040_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/17534666241280704","article-title":"Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United States","volume":"18","author":"Qiu","year":"2024","journal-title":"Ther Adv Respir Dis"},{"issue":"9","key":"10.1016\/j.chest.2026.03.040_bib13","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.3390\/jcm13092727","article-title":"Understanding patterns of adherence to antifibrotic treatment in idiopathic pulmonary fibrosis: insights from an Italian Prospective Cohort Study","volume":"13","author":"Iommi","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.chest.2026.03.040_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77837-x","article-title":"Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital","volume":"10","author":"Song","year":"2020","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.chest.2026.03.040_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261684","article-title":"Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real-world study","volume":"16","author":"Lee","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.chest.2026.03.040_bib17","article-title":"Clinical outcomes of dose modification during pirfenidone treatment for IPF: a nationwide post-marketing surveillance study","volume":"13","author":"Kang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.chest.2026.03.040_bib14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1513\/AnnalsATS.202407-717ED","article-title":"An eternal dilemma: exposing the impact of immortal time bias on antifibrotic effectiveness","volume":"21","author":"Kyle","year":"2024","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.chest.2026.03.040_bib18","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2024.09.030","article-title":"The impact of nintedanib dosing on clinical outcomes: an analysis of real-world data","volume":"167","author":"Limper","year":"2025","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2026.03.040_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","article-title":"Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis","volume":"200","author":"Dempsey","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2026.03.040_bib20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chest.2023.07.4215","article-title":"Comparing the utilization of antifibrotic medications based on income level","volume":"165","author":"Dempsey","year":"2024","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2026.03.040_bib21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1183\/13993003.01653-2015","article-title":"Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old","volume":"48","author":"Raghu","year":"2016","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2026.03.040_bib22","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1513\/AnnalsATS.201610-764OC","article-title":"Code-based diagnostic algorithms for idiopathic pulmonary fibrosis. Case validation and improvement","volume":"14","author":"Ley","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.chest.2026.03.040_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166462","article-title":"Burden of idiopathic pulmonary fibrosis progression: a 5-year longitudinal follow-up study","volume":"12","author":"Cottin","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.chest.2026.03.040_bib24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000504630","article-title":"Characterizing health outcomes in idiopathic pulmonary fibrosis using US health claims data","volume":"99","author":"Mortimer","year":"2020","journal-title":"Respiration"},{"issue":"3","key":"10.1016\/j.chest.2026.03.040_bib25","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.chest.2021.04.035","article-title":"Tobacco smoking and risk for pulmonary fibrosis: a prospective cohort study from the UK Biobank","volume":"160","author":"Bellou","year":"2021","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2026.03.040_bib26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1158\/1055-9965.EPI-08-0839","article-title":"A simulation study of control sampling methods for nested case-control studies of genetic and molecular biomarkers and prostate cancer progression","volume":"18","author":"Wang","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"10.1016\/j.chest.2026.03.040_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007866","article-title":"The impact of time-window bias on the assessment of the long-term effect of medication adherence: the case of secondary prevention after myocardial infarction","volume":"5","author":"Di Martino","year":"2015","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.chest.2026.03.040_bib28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/pds.3430","article-title":"Effect of evidence-based drug therapy on long-term outcomes in patients discharged after myocardial infarction: a nested case-control study in Italy","volume":"22","author":"Kirchmayer","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"10.1016\/j.chest.2026.03.040_bib29","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.chest.2026.03.040_bib30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12890-022-01953-9","article-title":"Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype","volume":"22","author":"Nili","year":"2022","journal-title":"BMC Pulm Med"},{"issue":"4","key":"10.1016\/j.chest.2026.03.040_bib31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s40801-022-00317-3","article-title":"Increased risk of stroke due to non-adherence and non-persistence with direct oral anticoagulants (DOACs): real-world analyses using a nested case-control study from The Netherlands, Italy and Germany","volume":"9","author":"Holthuis","year":"2022","journal-title":"Drugs Real World Outcomes"},{"issue":"10","key":"10.1016\/j.chest.2026.03.040_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37971","article-title":"Costs of prescription drugs for children and parental adherence to long-term medications","volume":"6","author":"Lauffenburger","year":"2023","journal-title":"JAMA Netw Open"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226004642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226004642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:42:21Z","timestamp":1791463341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369226004642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0012369226004642"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2026.03.040","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Antifibrotic Adherence and Dosing on Risk of Mortality and Hospitalization in Idiopathic Pulmonary Fibrosis","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2026.03.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}